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Abstract
Rationale: Noninvasive ventilation (NIV) is increasingly used in
patientswith acute respiratory distress syndrome (ARDS). The evidence
supporting NIV use in patients with ARDS remains relatively sparse.
Objectives: To determine whether, during NIV, the categorization
of ARDS severity based on the PaO2/FIO2 Berlin criteria is useful.
Methods:TheLUNGSAFE(LargeObservational Study toUnderstand
the Global Impact of Severe Acute Respiratory Failure) study described
the management of patients with ARDS. This substudy examines the
current practice of NIV use in ARDS, the utility of the PaO2/FIO2 ratio in
classifying patients receiving NIV, and the impact of NIV on outcome.
MeasurementsandMainResults:Of2,813patientswithARDS,436
(15.5%)weremanagedwithNIV onDays 1 and 2 following fulfillment of
diagnostic criteria.ClassificationofARDSseveritybasedonPaO2/FIO2 ratio
was associated with an increase in intensity of ventilatory support, NIV
failure, and intensive care unit (ICU) mortality. NIV failure occurred in
22.2% of mild, 42.3% of moderate, and 47.1% of patients with severe
ARDS. Hospital mortality in patients with NIV success and failure was
16.1% and 45.4%, respectively. NIV use was independently associated
with increased ICU (hazard ratio, 1.446 [95% confidence interval,
1.159–1.805]), but not hospital, mortality. In a propensity matched
analysis, ICUmortality was higher in NIV than invasively ventilated
patients with a PaO2/FIO2 lower than 150 mmHg.
Conclusions:NIVwasused in15%ofpatientswithARDS, irrespective
of severity category. NIV seems to be associated with higher ICU
mortality in patients with a PaO2/FIO2 lower than 150 mmHg.
Clinical trial registered with www.clinicaltrials.gov (NCT 02010073).
Keywords: noninvasive ventilation; acute respiratory distress
syndrome
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Noninvasive ventilation (NIV) has become
an established approach in the
management of patients with acute
respiratory failure, with strong evidence for
its benefits in patients with acute
exacerbations of chronic obstructive
pulmonary disease (1–3) and cardiogenic
pulmonary edema (4). NIV is not
uncommonly used in the management of
patients with acute respiratory distress
syndrome (ARDS) (5–7), as evidenced by
its formal recognition in the Berlin criteria
for ARDS introduced in 2012 (8).
Potential advantages of NIV in the
management of patients with ARDS are
mainly related to the avoidance of
complications linked to sedation, muscle
paralysis, and ventilator-associated
complications associated with endotracheal
intubation and invasive mechanical ventilation
(MV) (9). Initially, the use of NIV in patients
with ARDS focused on immunocompromised
patients, such as those with hematologic
malignancies (10–14). However, NIV has been
used in a broader selection of patients with
ARDS (7). Of concern, the evidence
supporting NIV use in patients with ARDS is
based on relatively small samples (5, 15).
Moreover, in most studies, patients treated
with NIV were compared with patients treated
with oxygen administration (16) or with
historical cohorts (17).
Several concerns exist regarding the use
of NIV in patients with ARDS. The
subgroup of ARDS most likely to benefit
from NIV remains unclear. Although some
literature suggests that NIV may best be
reserved for patients with mild ARDS
(i.e., patients with a PaO2/FIO2 ratio of
200–300 mm Hg) (5, 15, 18, 19), it is not
always the case in practice (20). Although
some factors leading to NIV failure in
patients with ARDS are better understood,
relatively few patients have been studied to
date (21, 22). The impact of NIV on
outcome in ARDS is therefore not well
understood. In particular, concerns have
been raised regarding the impact of
prolonged NIV in the absence of respiratory
status improvement, potentially delaying
tracheal intubation and invasive MV (20, 21,
23, 24). Finally, the recent Berlin definition
of ARDS does not specify whether patients
with ARDS managed with NIV should be all
classified as having “mild” ARDS or whether
the PaO2/FIO2 ratio severity stratification is
more appropriate (25).
For these reasons, a key prespecified
secondary aim of the LUNG SAFE (Large
Observational Study to Understand the
Global Impact of Severe Acute Respiratory
Failure) (26) study was to describe the
current practice of the use of NIV in ARDS.
Our primary objective was to determine the
proportion of patients managed with NIV
on Days 1 and 2 following fulfillment of
diagnostic criteria for ARDS. Secondary
objectives included determining the utility
of the PaO2/FIO2 ratio severity categories
in the classification of NIV patients,
characteristics of patients managed with
NIV, ventilatory settings used in these
patients, factors associated with NIV
failure, and the association between
NIV use and mortality in patients
with ARDS.
Methods
LUNG SAFE was a prospective,
observational, international multicenter
cohort study. Detailed methods have been
published elsewhere (26), and are also
available in the online supplement.
Patients, Study Design, and Data
Collection
Patients receiving invasive MV or NIV were
enrolled in the participating intensive care
units (ICUs) for 4 consecutive weeks.
Exclusion criteria were age less than 16 years
or inability to obtain informed consent.
Following enrollment, patients were
evaluated daily for acute hypoxemic
respiratory failure (AHRF), defined as
PaO2/FIO2 less than or equal to 300 mm Hg
while simultaneously receiving invasive MV
or NIV (depending on the patient group)
with end-expiratory pressure greater than
or equal to 5 cm H2O, and new radiologic
pulmonary parenchymal abnormalities. For
*A complete list of LUNG SAFE national coordinators, site investigators, and national societies endorsing the study may be found in the online supplement.
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At a Glance Commentary
Scientific Knowledge on the
Subject: Noninvasive ventilation
(NIV) is used to treat patients with
acute respiratory distress syndrome
(ARDS). Current worldwide practice
in the use of this technique, its
implications for patient management,
and association with outcome are
poorly understood. The Berlin
definition of ARDS is unclear in regard
to the severity classification of patients
with NIV.
What This Study Adds to the
Field: NIV is used in about 15% of
patients with ARDS, irrespective of the
severity of hypoxemia. Classification of
ARDS severity in patients with NIV
based on PaO2/FIO2 ratio had
management and prognostic
significance. Use of NIV, in
comparison with invasive ventilation,
has important implications for patient
management. Although mortality rate
was low in patients successfully
managed with NIV, patients who
failed NIV had a high mortality. NIV
may be associated with a worse
intensive care unit outcome than
invasive mechanical ventilation in
moderate to severe ARDS.
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patients fulfilling AHRF criteria a more
detailed set of data was recorded, to
determine whether the patient fulfilled the
Berlin criteria for ARDS.
Data on arterial blood gases, type of
ventilatory support/settings, and Sequential
Organ Failure Assessment (SOFA) score
were collected on selected days during the
ICU stay. Data were collected once per day,
as close as possible to 10:00 A.M. Data
on ventilatory settings were recorded
simultaneously with arterial blood gas
analysis. Decisions to withhold or withdraw
life-sustaining treatments and their timing
were recorded. ICU and hospital survival
were collected at the time of discharge,
censored at 90 days after enrollment.
We assessed clinician recognition of
ARDS at two time points: on Day 1 of study
entry, andwhenpatients exited the study.ARDS
was deemed to have been clinician-recognized
if either question was answered positively.
NIV Patient Cohort and Definitions
We restricted analyses to the subset of
patients (93%) fulfilling ARDS criteria on Day 1
or 2 following the onset of AHRF. Patients were
classified as “NIV patients” if they received NIV
on Day 1 and 2 following fulfillment of ARDS
criteria. In all NIV patients, arterial blood gas
measurements were taken while the patient was
receiving NIV. Patients were classified as
“invasive-MV patients” if they received invasive
MV on Day 1 and/or Day 2 of ARDS (see
Table E1 in the online supplement).
NIV definition encompassed all forms
of patient interface and ventilatory modes.
High-flow oxygen therapy was not included.
Because data were collected once per day and
the duration of NIV sessions was not
recorded, patients that were switched from
NIV to invasive-MV before the Day 2 data
collection (n = 75) were classified in the
invasive-MV group. We considered that, in
these patients, the NIV session may have
been too short to be meaningful.
NIV failure was defined as the need to
switch to invasive-MV after Day 1 and 2 of
NIV. We limited the comparison of NIV
“success” and “failure” groups to patients
without treatment limitation (whose definition
encompassed all forms of treatment limitation)
unless this occurred after institution of invasive
MV (see also STATISTICAL ANALYSIS).
Statistical Analysis
For continuous variables, we reported
median with interquartile range or
mean6 SD, and for categorical variables,
we reported proportions. Student’s t test,
analysis of variance, Wilcoxon rank sum
test, or Kruskal-Wallis, chi-square, or
Fisher tests were used when appropriate.
Multivariate Cox proportional hazards
models were applied to investigate the
relationship between potential covariates and
outcomes (ICU and hospital mortality, NIV
failure). Propensity score matching method
was used to evaluate the possible different
treatment effects (invasive-MV and NIV) on
survival (see Table E2). Patients were matched
(1:1 match without replacement) using a
caliper of 0.2 SD of the logit of the propensity
score. For all tests, a two-sided a of 0.05 was
considered significant. The analyses were
performed using SAS (SAS Institute, Cary,
NC) and R (The R Foundation for Statistical
Computing, Vienna, Austria) software.
Results
Incidence of NIV Use
A total of 459 ICUs enrolled patients in the
study and 422 enrolled patients with ARDS. In
the ICUs enrolling patients with ARDS, 207
(49.1%) usedNIV onDays 1 and 2 of ARDS, in
at least one patient. Of the 2,813 patients that
developed ARDSwithin 2 days of AHRF onset,
507 patients received NIV on Day 1 (18%).
Of these, 436 (15.5%) were managed with NIV
on Days 1 and 2, and constitute the study
population (Figure 1), whereas 75 patients
were managed with NIV on Day 1 and on
invasive MV on Day 2 (see Table E3).
Continuous positive airway pressure
was used in 28.2% of patients in the NIV group
(Table 1), whereas the remaining patients were
managed with pressure cycled modes.
Classification of NIV Patients
In patients with ARDS managed with NIV,
classification of severity intomild,moderate, and
severe categories according to the PaO2/FIO2
bands in the Berlin definition was associated
with a step-wise increase in positive end-
expiratory pressure (PEEP) and FIO2 (Table 1).
Greater ARDS severity category was associated
with an increase in clinician recognition of
ARDS, and a worsening in outcomes, including
ICU length of stay, ICU mortality, and
nonsignificant increase in hospital mortality
(Table 2). Increasing ARDS severity category
was associated with a significant increase in
NIV failure in patients without preintubation
treatment limitations (from 22.2 to 42.3 to
47.1%; P= 0.008).
Of interest, the use of NIV did not vary
significantly with mild (14.3%), moderate
(17.3%), and severe (13.2%) ARDS severity
category (Table 1).
Baseline Characteristics of NIV
Patients
NIV patients were older and had lower
nonpulmonary SOFA scores, both in the
whole population and across the different
severity categories, compared with invasive-
MV patients (Table 1). NIV patients had a
higher prevalence of chronic renal failure,
congestive heart failure, and chronic
obstructive pulmonary disease than
invasive-MV patients (Table 1). The
prevalence of immunosuppression and/or
malignancies did not differ between the
two groups. Clinician recognition of
ARDS was significantly lower in NIV
patients compared with invasive-MV
patients (Table 2). The use of NIV was
independently associated with a lower
recognition of ARDS by clinicians (odds
ratio, 0.585; 95% confidence interval,
0.45–0.76) (see Table E4). ARDS recognition
was increased in patients that failed NIV
(Table 3). There were no differences in
treatment limitation rates in NIV patients
versus invasive-MV patients.
Effect of NIV versus Invasive MV on
Ventilation and Gas Exchange
NIV patients had significantly lower levels
of PEEP, and higher respiratory rates than
invasive-MV patients. In NIV patients,
measured tidal volumes and minute
ventilation were greater than in invasive-
MV patients (Table 1). In contrast to
patients managed with invasive-MV, tidal
and minute ventilation did not change
significantly with greater ARDS severity
(Table 1).
At ARDS onset, PaO2/FIO2 ratio was not
different between the NIV and invasive-
MV patients (Table 1). PaO2/FIO2 ratios
improved more rapidly in the patients
treated with invasive-MV (Figure 2B; see
Figure E1). Baseline PaCO2 did not differ
between the NIV and invasive-MV patients.
However, although baseline PaCO2 in mild
ARDS was higher in NIV compared with
invasive-MV patients (486 18 vs. 416
10 mm Hg; P = 0.002), PaCO2 in severe
ARDS was lower in NIV (436 14 vs. 526
18 mm Hg; P, 0.001) compared with
invasive-MV. In contrast to invasive-MV
patients, where PaCO2 increased, the
PaCO2 in the NIV group did not change
ORIGINAL ARTICLE
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(P = 0.134) with greater ARDS severity
(Table 1, Figure 2).
NIV Failure versus Success
Among the 349 NIV patients without
preintubation treatment limitations, 131
(37.5%) failed NIV (Table 3). A multivariate
Cox model revealed that higher
nonpulmonary SOFA score, lower
PaO2/FIO2, and the percentage increase of
PaCO2 over the first 2 days of treatment
were independently associated with NIV
failure within 28 days from AHRF onset
(see Table E5).
Effect of Intubation on Physiologic
Variables
Table E6 and Figure 2C show the
comparison, for physiologic variables,
between the last available recording of
NIV and the first available recording
during invasive-MV. After intubation,
both PaO2/FIO2 (1526 68 vs. 1826
95 mm Hg; P, 0.001) and PaCO2
significantly increased. After initiation
of invasive-MV, patients were managed
with a higher PEEP and had lower
respiratory rates, and received lower
tidal and minute volumes compared
with preintubation values.
Outcomes in NIV Patients
Crude ICU and hospital mortalities were not
significantly different between the NIV and
the invasive-MV patients (Table 2; see
Figure E2).
Patients that failed NIV were more
severely ill (Table 3) and had significantly
worse ICU (42.7% vs. 10.6%; P, 0.001)
and hospital mortality compared with those
that were successfully managed with NIV
(Table 3).
In a multivariate Cox regression model
adjusting for covariates significantly
associated with outcome (see Table E7),
NIV use was independently associated with
increased ICU (but not hospital) mortality
rate (hazard ratio, 1.446 [95% confidence
interval, 1.159–1.805]). Furthermore, we
matched 353 NIV patients with invasive-
MV patients using propensity score (see
Table E2). The two matched populations
were homogeneous for demographic
characteristics, comorbidities, and severity
of organ failures (see Table E2). ICU and
hospital mortality rates did not differ
(Table 4). Kaplan-Meier survival estimates
for invasive-MV and NIV patients of the
matched samples were not significantly
different (Figure 3). In the subset of patients
with a PaO2/FIO2 ratio less than 150, ICU
mortality was 36.2% with NIV compared
with 24.7% with invasive-MV (P = 0.033)
(Table 4). Figure 3 shows survival curves in
NIV and invasive-MV groups for matched
patients with a PaO2/FIO2 higher and lower
than 150 mm Hg.
Table E8 shows the comparison
between survivors and nonsurvivors at
hospital discharge in NIV patients.
Nonsurvivors were older, with a higher
prevalence of immunosuppression or
neoplastic disease, and had a higher
nonpulmonary SOFA score. Moreover,
nonsurvivors had, on the day of ARDS
diagnosis, a lower PaO2/FIO2 and higher
respiratory rate than survivors. A
multivariate Cox model performed on
baseline characteristics in the NIV group
showed that chronic heart failure, presence
of hematologic or neoplastic disease,
chronic liver failure, age, ARDS severity,
percentage decrease of PaO2/FIO2 ratio
between Days 1 and 2, total respiratory rate,
Patients with ARDS
3,022
Patients with ARDS after
2 days from AHRF onset
209 (6.9%)
Patients with ARDS within
2 days of AHRF onset
2,813 (93.1%)
Patients invasively ventilated*
2,377 (84.5%)
Patients non-invasively
ventilated on Day 1 and 2
436 (15.5%)
Non-survivors§
462 (25.7%)
Survivors§
1,337 (74.3%)
Survivors§
71 (54.6%)
Survivors§
183 (83.9%)
Survivors§
25 (28.7%)
Survivors§
79 (13.7%)
Non-survivors§
499 (86.3%)
Non-survivors§
59 (45.4%)
Non-survivors§
35 (16.1%)
Non-survivors§
62 (71.3%)
No limitation of care†
1,799 (75.7%)
Limitation of care†
578 (24.3%)
Limitation of care†
87 (20.0%)
Failure‡
131 (30.0%)
Non-failure‡
218 (50.0%)
Severity at ARDS onset
Mild 714 (30.0%)
Moderate 1,106 (46.5%)
Severe 557 (23.4%)
Severity at ARDS onset
Mild 119 (27.3%)
Moderate 232 (53.2%)
Severe 85 (19.5%)
Figure 1. Flowchart of the study population. *Seventy-five patients received noninvasive ventilation on Day 1 and invasive ventilation at Day 2. †Limitation
of care before acute hypoxemic respiratory failure (AHRF) onset or within 28 days. ‡Failure of noninvasive ventilation was evaluated within
28 days from AHRF onset. xWe reported vital status at hospital discharge censored at Day 90 after AHRF onset. Vital status was unknown
for nine patients: eight invasively ventilated and one noninvasively ventilated within 48 hours from AHRF onset. ARDS = acute respiratory distress
syndrome.
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and nonpulmonary SOFA score were each
independently associated with risk of
in-hospital death (see Table E9).
Discussion
Of the 2,813 patients that were diagnosed
with ARDS criteria within 2 days of
developing AHRF enrolled into the LUNG
SAFE study, 436 (15.5%) were managed
with NIV on Days 1 and 2 of ARDS. NIV
patients were older and had more
comorbidities, but had lower nonpulmonary
SOFA scores compared with invasive-MV
patients. NIV failure occurred in 134
(30.7%) patients, necessitating change to
invasive-MV. Classification of ARDS
severity based on PaO2/FIO2 ratio categories
was indicative of a higher intensity of
treatment and worse outcome, as is seen
in patients with ARDS managed with
invasive-MV. Of interest, NIV applications
rates were similar across the ARDS severity
categories. Although crude mortality was
not different, after adjustment for
covariates NIV was associated with
increased ICU (but not hospital) mortality.
This finding appeared confined, in the
propensity matched analysis, to the more
severe patients (i.e., those with a PaO2/FIO2
ratio ,150 mm Hg).
The finding that NIV use was similar
across the ARDS severity categories
was surprising given the fact that
recommendations for NIV use in ARDS
suggest that its use be restricted to mild
ARDS (19). Although success rates of NIV
in mild ARDS were 78%, this decreased to
58% in moderate and 53% in severe ARDS,
consistent with previous findings (24).
Although NIV has been shown to be
beneficial in the subgroup of patients with
immunosuppression/neoplastic diseases
(10–14), the presence of these diseases was
not associated with a greater use of NIV in
our patients. NIV use seemed associated
with other factors, such as preexisting
chronic obstructive pulmonary disease,
congestive heart failure, and chronic renal
failure.
Although the Berlin definition
clearly acknowledges that ARDS
diagnosis can be fulfilled by patients
undergoing NIV, the definition is less
clear concerning how ARDS severity
should be determined in these patients.
Although some authors used the
PaO2/FIO2 severity bands also for NIV
patients (27), others considered that NIV
patients with PaO2/FIO2 less than 200 mm
Hg could not be classified according to
Berlin definition and these patients were
excluded from analysis (25). Our results
support the use of PaO2/FIO2 bands to
classify NIV patients as mild, moderate,
and severe: worsening ARDS categories
were associated with more prolonged
and aggressive ventilator support, and
worse patient outcomes.
The use of NIV was associated with
important differences in the clinical
management of patients with ARDS, which
might be, in part, explained by the fact that
use of NIV was independently associated
with an underrecognition of ARDS by
clinicians both at study entry and any time.
Interestingly, clinicians recognized ARDS
much more frequently in patients that failed
NIV, as shown by the very high rate of
delayed recognition in these patients. NIV
patients received lower levels of PEEP (with
a median value of 7 cm H2O) in all the
ARDS categories and a predominant use of
FIO2 to correct hypoxemia. This finding is
clinically relevant, because application of
higher levels of PEEP has been associated
with improved outcomes in patients with
moderate to severe ARDS (28). Although
the use of lower PEEP may be seen as
inherent to the use of NIV, because of
constraints in increasing airway pressure,
our results also highlight the effects of the
lack of control over respiratory drive.
Minute ventilation was higher in NIV
patients as a result of higher respiratory
rate and tidal volumes. Tidal volumes
were also higher than the 6–8 ml/kg of
ideal body weight recommended for
lung-protective ventilation. These data
should be interpreted cautiously, because
they were measured only in a subset of NIV
Table 2. Events Occurring during Follow-up in Study Population (Stratified by ARDS Severity and Ventilation)
ARDS, Mild ARDS, Moderate ARDS, Severe ARDS P Value
within
NIV
P Value
within
Invasive-MVNIV Invasive-MV NIV Invasive-MV NIV Invasive-MV NIV Invasive-MV
N 119 714 232 1,106 85 557 436 2,377 — —
Clinical recognition of
ARDS, n (%)
At study entry 21 (17.6) 178 (24.9) 63 (27.2) 372 (33.6) 17 (20.0) 236 (42.4)* 101 (23.2)* 786 (33.1) 0.101 ,0.001
At any time 41 (34.5) 366 (51.3)* 122 (52.3) 722 (65.3)* 47 (55.3) 437 (78.5)* 210 (48.2) 1,525 (64.2)* 0.002 ,0.001
Patients with
treatment
limitation, n (%)
27 (22.7) 171 (23.9) 68 (29.3) 272 (24.6) 29 (34.1) 135 (24.2) 124 (28.4) 578 (24.3) 0.186 0.951
Length of stay (from
ARDS
onset) in ICU (d),
median (IQR)
All patients 6 (3–10) 8 (4–16)* 8 (4–13.5) 10 (5–19)* 7 (4–12) 10 (4–18)* 7 (4–12) 9 (5–18)* 0.032 0.019
Alive patients at
ICU discharge
5 (3–8) 9 (5–18)* 8 (4–13) 11 (6–20)* 7 (4–13) 13 (7–23)* 7 (4–12) 11 (6–20)* 0.002 ,0.001
ICU mortality, n (%) 26 (21.8) 191 (26.8) 64 (27.8) 351 (31.7) 34 (40.0) 221 (39.7) 124 (28.4) 763 (32.1) 0.017 ,0.001
Hospital mortality, n (%) 36 (30.3) 249 (34.9) 83 (35.8) 446 (40.3) 37 (43.5) 257 (46.4) 156 (35.8) 952 (40.1) 0.130 ,0.001
Definition of abbreviations: ARDS = acute respiratory distress syndrome; ICU = intensive care unit; IQR = interquartile range; MV =mechanical ventilation;
NIV = noninvasive ventilation.
Vital status was evaluated at ICU/hospital discharge. Patients who were still in ICU/hospital were censored on Day 90 from acute hypoxemic respiratory
failure onset.
*P, 0.05, comparison versus NIV group with same ARDS severity.
ORIGINAL ARTICLE
72 American Journal of Respiratory and Critical Care Medicine Volume 195 Number 1 | January 1 2017
patients and limitations exist regarding the
accuracy of measurement of tidal volume
during NIV. In NIV patients, minute
ventilation increased with greater ARDS
severity during NIV with no significant
difference in PaCO2, suggesting that the
increased patient respiratory drive
compensated for the increased dead space.
In patients failing NIV, institution of
invasive-MV was associated with increased
PEEP, decreased oxygen fraction, and
improved PaO2/FIO2 ratios, as well as
decreases in tidal volume and respiratory
rate leading to an approximately 30% drop
of minute ventilation, resulting in an
increased PaCO2. Ventilator settings in
patients transitioned to invasive-MV were
closer to protective settings than those seen
before NIV failure, suggesting that
institution of invasive-MV (which might
have required increased sedation)
facilitated better control of tidal volume
and airway pressures, possibly decreasing
the risk of lung injury.
NIV failure was associated with a
substantial increase in the risk of death, with
mortality higher than for severe ARDS
managed with invasive-MV. Although this
finding may reflect the fact that these
patients were sicker at commencement of
NIV, and worsened over time, it underlines
the need for careful patient selection when
considering NIV use in ARDS. Factors
Table 3. Demographic and Clinical Characteristics of ARDS NIV Patients at Baseline (ARDS Onset)
ARDS-NIV (without Treatment Limitations)
P ValueSuccess Failure
Patients, n (%) 0.001
All 218 (62.5) 131 (37.5)
Mild ARDS 77 (77.8) 22 (22.2)
Moderate ARDS 105 (57.7) 77 (42.3)
Severe ARDS 36 (52.9) 32 (47.1)
Male, n (%) 129 (59.2) 80 (61.1) 0.727
Age, median (IQR) 66.5 (52 to 78) 63.0 (53 to 74) 0.081
ICU mortality, n (%)
All 23 (10.6) 56 (42.7) ,0.001
Patients with PaO2/FIO2 ratio ,150 mm Hg 13 (14.6) 36 (45.0) ,0.001
Patients with PaO2/FIO2 ratio >150 mm Hg 10 (7.8) 20 (39.2) ,0.001
Hospital mortality, n (%) 35 (16.1) 59 (45.4) ,0.001
Clinical recognition of ARDS, n (%)
At study entry 43 (19.7) 42 (32.1) 0.009
At any time 73 (34.1) 88 (68.2) ,0.001
Risk factors for ARDS, n (%) 0.211
None 33 (15.1) 12 (9.2)
Nonpulmonary 27 (12.4) 14 (10.7)
Pulmonary 158 (72.5) 105 (80.1)
Comorbidities, n (%)
Diabetes 56 (25.7) 21 (16.0) 0.035
Chronic renal failure 36 (16.5) 11 (8.4) 0.032
Heart failure (NYHA III-IV) 28 (12.8) 18 (13.7) 0.811
Chronic liver failure 4 (1.8) 2 (1.5) 1.000
Neoplasm or immunosuppression 42 (19.3) 34 (26.0) 0.143
COPD 74 (33.9) 33 (25.2) 0.086
Home ventilation 13 (6.0) 5 (3.8) 0.380
Parameters at day of ARDS onset, mean6 SD
PaO2, mm Hg 88.66 31.6 83.16 30.5 0.097
FIO2 0.586 0.22 0.636 0.21 0.007
PaO2/FIO2 ratio, mm Hg 1716 65 1456 60 ,0.001
pH 7.386 0.09 7.386 0.09 0.967
PaCO2, mm Hg 486 17 446 17 0.009
Base excess, mmol/L 1.916 6.73 20.026 6.83 0.002
PEEP, cm H2O 76 2 76 2 0.478
Total respiratory rate, breaths/min 256 6 276 8 0.012
Minute ventilation, L/min 12.716 5.07 14.036 6.25 0.107
Tidal volume, ml/kg PBW 8.386 2.60 8.656 3.11 0.795
Nonpulmonary SOFA score adjusted 26 3 36 3 0.019
Patients under pressors agents, n (%) 23 (11.7) 18 (15.1) 0.376
Use of CPAP, n (%) 59 (27.1) 35 (26.7) 0.907
Definition of abbreviations: AHRF = acute hypoxemic respiratory failure; ARDS = acute respiratory distress syndrome; COPD = chronic obstructive
pulmonary disease; CPAP = continuous positive airway pressure; ICU = intensive care unit; IQR = interquartile range; NIV = noninvasive ventilation;
NYHA =New York Heart Association; PBW= predicted body weight; PEEP = positive end-expiratory pressure; SOFA = Sequential Organ Failure
Assessment
Population was stratified according to the NIV treatment outcome (success-failure) occurring in ICU during 28 days from AHRF onset. Patients with
preintubation treatment limitations were excluded from this analysis. Vital status was evaluated at ICU/hospital discharge. Patients who were still in
ICU/hospital were censored on Day 90 from AHRF onset.
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Figure 2. Differences in physiologic variables for patients treated with invasive and noninvasive ventilation. (A) Although for mild acute
respiratory distress syndrome (ARDS) PaCO2 was significantly higher in patients managed with noninvasive ventilation, the opposite was true for
severe ARDS, for which PaCO2 was lower in patients treated with noninvasive ventilation. *P, 0.05, comparison between invasive mechanical
ventilation (MV) and noninvasive ventilation (NIV) group. (B) Although PaO2/FIO2 was not different over the first 2 days in patients managed with
noninvasive and invasive ventilation, this improved more rapidly in the patients managed with invasive ventilation (for NIV, n = 422, 421, 382,
293, 228, 149, 94, 50, and 18, from Day 1 to 28). *P, 0.05, comparison between invasive-MV and NIV group. (C) Relative differences
(increase of decrease) of selected physiologic variables between the last day of noninvasive ventilation and the first day of invasive ventilation,
in the subset of patients with noninvasive ventilation failure. †P, 0.05. On each box, the bottom line denotes the first quartile value, the middle
line denotes the median value, and the top line represents the third quartile value. The whiskers are drawn out and the extreme values are
calculated as: lower fence = first quartile 2 1.53 interquartile range; upper fence = third quartile 1 1.53 interquartile range. PEEP = positive
end-expiratory pressure.
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independently associated with NIV failure
included higher nonpulmonary SOFA score
and higher respiratory rate. Evaluating the
patient’s response to NIV is also important,
with the percentage increase of PaCO2 over
the first 2 days of treatment also associated
with NIV failure. A decline of PaO2/FIO2
ratio between Day 1 and 2 of treatment
was independently associated with an
increased mortality in NIV patients. These
parameters could be used to stratify
patients when deciding to treat patients
with NIV or in deciding to terminate NIV
and proceed to invasive-MV.
Of concern is the finding that NIV use
seems to be associated with increased ICU
mortality. After adjusting for potential
confounders, a patient treated with NIV at
ARDS onset seemed to have a 30% increased
risk of dying in ICU compared with a similar
patient treated with invasive-MV. This
result should be interpreted cautiously,
because it was not confirmed for the hospital
mortality and is partly discrepant with the
propensity matched analysis (affected by a
lower power because of the smaller number
of patients included). Finally, although the
model did not highlight any effect of the
interaction between NIV and PaO2/FIO2 ratio
on mortality, in the propensity matched
cohort, the ICU mortality was significantly
higher for NIV than for invasive-MV in the
cohort of patients with PaO2/FIO2 less than
150 mm Hg. In this respect our data are
consistent with previous reports showing
an increase in NIV failure rates, in patients
with a PaO2/FIO2 ratio less than or equal to
150 mm Hg (29).
The LUNG SAFE study represents one
of the largest prospective datasets of patients
with ARDS treated with NIV. Nonetheless,
it does have limitations. To limit the burden
Table 4. Effect of Treatment and Clinical Parameters at ARDS Onset for Invasive-MV and NIV Patients in the Propensity Score
Matched Sample
Invasive-MV Patients
(n = 353)
NIV Patients
(n = 353) P Value
ARDS severity at onset, n (%)
Mild 100 (28.33) 101 (28.61) 1.000
Moderate 184 (52.12) 165 (46.74) 0.195
Severe 69 (19.55) 87 (24.65) 0.127
Patients with PaO2/FIO2 ratio ,150 mm Hg at ARDS
onset, n (%)
174 (49.29) 174 (49.29) 1.000
Parameters at ARDS onset, mean6SD
pH 7.356 0.11 7.386 0.09 0.001
FIO2 0.666 0.24 0.606 0.22 0.001
SPO2, % 94.536 5.51 94.996 3.85 0.660
Total respiratory rate, breaths/min 20.666 6.46 25.636 7.01 ,0.001
PEEP, cm H2O 8.096 3.1 7.026 1.95 ,0.001
Peak inspiratory pressure, cm H2O 26.776 7.66 17.436 7.22 ,0.001
PaO2, mm Hg 94.646 40.32 87.966 32.55 0.031
PaCO2, mm Hg 46.56 14.41 45.86 17.36 0.320
PaO2/FIO2, mm Hg 157.626 65.58 160.946 64.29 0.492
Tidal volume, ml/kg PBW 7.536 1.75 8.466 2.77 0.001
Minute ventilation, L/min 9.316 2.90 13.266 5.60 ,0.001
Base excess, mmol/L 20.746 5.93 0.606 6.55 0.002
HCO3, mmol/L 24.396 5.65 25.46 6.95 0.086
Nonpulmonary SOFA adjusted 3.266 2.82 3.196 2.84 0.423
D (%)* PaO2/FIO2 ratio 36.316 76.76 28.176 76.77 0.063
D (%)* PaCO2 20.36 29.86 3.376 25.92 0.025
Use of vasopressors, n (%) 80 (24.32) 49 (15.03) 0.005
Duration of mechanical ventilation, d, median (IQR)
All patients 8 (4 to 15) 9 (5 to 13) 0.293
ICU survivors 7 (4 to 14) 10 (7 to 13) 0.744
Length of ICU stay, d, median (IQR)
All patients 10 (6 to 18) 7 (4 to 12) ,0.001
ICU survivors 10 (6 to 19) 7 (4 to 12) ,0.001
All-cause in-ICU mortality, n (%)
All patients 92 (26.06) 99 (28.05) 0.608
Matched patients with PaO2/FIO2 ratio ,150 mm Hg 43 (24.71) 63 (36.21) 0.033
All-cause in-hospital mortality, n (%)
All patients 115 (32.76) 117 (33.24) 0.871
Matched patients with PaO2/FIO2 ratio ,150 mm Hg 55 (31.61) 66 (38.15) 0.224
Definition of abbreviations: AHRF = acute hypoxemic respiratory failure; ARDS = acute respiratory distress syndrome; ICU = intensive care unit; IQR =
interquartile range; MV =mechanical ventilation; NIV = noninvasive ventilation; PBW= predicted body weight; PEEP = positive end-expiratory pressure;
SOFA = Sequential Organ Failure Assessment.
Statistical tests accounted for the matched nature of the sample (paired Student’s t test or Wilcoxon signed rank test for continuous variables, McNemar
test for dichotomous variables). For three patients (two invasive-MV and one NIV) vital status at hospital discharge were missing. Vital status was evaluated
at ICU/hospital discharge. Patients who were still in ICU/hospital were censored on Day 90 from AHRF onset.
*Delta (D) was evaluated as difference between the value measured at the second day from ARDS onset and those measured at the ARDS onset day.
Percentage was evaluated as rate between D and value measured at the ARDS onset day.
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on investigators, data were collected as often
as once per day and we did not collect hours
of duration of NIV treatment, a factor
previously thought to be important in NIV
success and failure (30). For this reason, we
conservatively considered NIV patients as
only those undergoing this treatment on
Days 1 and 2. Patients treated with NIV for
a shorter period and subsequently intubated
were considered in the invasive MV group.
This was done to avoid considering as NIV
patients those receiving only a short NIV
trial, or who entered the ICU while receiving
NIV, and were subsequently intubated
quickly. In these patients, it seems likely that
the impact of invasive MV would likely have
the predominant effect on patient outcome.
Clearly, a drawback of this approach is the
potential underestimation of NIV failure
rate. We did not include patients undergoing
high-flow oxygen, because these patients did
not fulfill the Berlin criteria for ARDS
(31, 32). We did not collect data on the type
of interface used for NIV, which may be a
potentially important determinant of NIV
success (33). Moreover we did not collect
patients’ severity scores, such as Acute
Physiology and Chronic Health Evaluation
and Simplified Acute Physiology Score, but
relied on the SOFA score to characterize the
nonpulmonary severity of illness severity.
Finally, although we collected data regarding
the presence of treatment limitation
decisions, we cannot completely exclude the
possibility that clinicians may have been
reluctant to use invasive-MV in patients
at higher risk of dying because of
preexisting medical conditions (as suggested,
for example, by older age of the NIV
patients).
In conclusion, in a large cohort
of patients with ARDS, NIV was used in
15% of cases, and was used to a similar
extent across the severity categories.
NIV failure occurred in more than
one-third of patients with ARDS
and in almost half of patients with
moderate and severe ARDS. Mortality
rates in patients that failed NIV were
high. Of concern, NIV was associated
with a worse adjusted ICU mortality
than invasive-MV in patients with a
PaO2/FIO2 lower than 150 mm Hg.
These findings raise further
concerns regarding NIV use in this
patient group. n
Author disclosures are available with the text
of this article at www.atsjournals.org.
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